Related Experiment Video
Updated: Apr 18, 2026

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
Published on: February 12, 2017
Future options for ALK-positive non-small cell lung cancer
Daniela Iacono1, Rita Chiari2, Giulio Metro2
1Medical Oncology, Santa Maria della Misericordia Hospital, Azienda Ospedaliera di Perugia, Perugia, Italy; Medical Oncology, University of Rome 'La Sapienza', Sant'Andrea Hospital, Rome, Italy.
Targetable genetic alterations like anaplastic lymphoma kinase (ALK) rearrangements drive non-small cell lung cancer (NSCLC). ALK-tyrosine kinase inhibitors (TKIs) offer effective treatments, with newer drugs showing promise against resistance mechanisms.
Area of Science:
- Oncology
- Molecular Biology
- Pharmacology
Background:
- Non-small cell lung cancer (NSCLC) harbors targetable genetic alterations.
- Anaplastic lymphoma kinase (ALK) gene rearrangements are key drivers in specific NSCLC subsets.
- ALK dysregulation leads to uncontrolled cancer cell proliferation, making it a therapeutic target.
Purpose of the Study:
- To review current knowledge on ALK-positive advanced NSCLC.
- To discuss emerging ALK-tyrosine kinase inhibitors (TKIs) and combination regimens.
- To explore the future treatment landscape for ALK-positive NSCLC.
Main Methods:
- Review of current scientific literature on ALK-positive NSCLC.
- Analysis of clinical development of ALK-TKIs.
- Discussion of resistance mechanisms and novel therapeutic strategies.
Main Results:
- Crizotinib, the first ALK-TKI, demonstrated superior efficacy over chemotherapy in advanced NSCLC.
- Second-generation ALK-TKI ceritinib shows high activity in both crizotinib-pretreated and -naïve patients.
- Understanding resistance mechanisms is crucial for evolving treatment strategies.
Conclusions:
- ALK-TKIs represent a significant advancement in treating ALK-positive NSCLC.
- Ongoing research into novel drugs and combinations aims to overcome resistance.
- The treatment paradigm for ALK-positive NSCLC is rapidly evolving.
More Related Videos
Related Concept Videos
Targeted Cancer Therapies
There are several types of targeted therapies against...
Treatment Resistent Cancers
Tumor Immunotherapy
Treatment Resistant Cancers
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...

